Sarepta Therapeutics compartio una carta a la comunidad Duchenne:

#TheAkariFoundation #sanantoniotexas #enfermedadesraras #DistrofiaMuscularDeDuchenne #duchenneenespañol #SareptaTherapeutics #AMONDYS45 #VYONDYS53 #ESSENCE #AkariMarzo

Sarepta Therapeutics comparte a la Comunidad Duchenne:

Nos complace compartir que a inicios de esta semana, los datos de dos años del estudio EMBARK – un estudio pivotal de Fase 3 que evalúa Elevidys – fueron publicados en la revista Neurology and Therapy.

#TheAkariFoundation #SareptaTherapeutics

Sarepta Therapeutics nos comparte lo que ha cambiado con la actualización de la información de la receta (también conocida como “la etiqueta”) de ELEVIDYS (delandistrogene moxeparvovec-rokl), la única terapia aprobada para la distrofia muscular de Duchenne.

#TheAkariFoundation #SareptaTherapeutics

Sarepta Therapeutics nos comparte;

#TheAkariFoundation #sanantoniotexas #enfermedadesraras #DistrofiaMuscularDeDuchenne #duchenneenespañol #SareptaTherapeutics #ESSENCE #VYONDYS53 #AMONDYS45 #AkariNoviembre

Sarepta anuncia la completación de su compromiso del ensayo confirmatorio para sus terapias de morfolino fosforodiamidato (PMOs, por sus iniciales en inglés) AMONDYS 45 y VYONDYS 53 para las enfermedades muy raras

🔗Lee el artículo completo aquí: lnkd.in/e9NRG_B3

#SareptaTherapeutics

Sarepta Therapeutics comparte actualización del estudio clínico:

Los resultados principales de ESSENCE, un estudio aleatorizado, doble ciego, controlado con placebo, de Fase 3, global, de golodirsen y casimersen en 225 pacientes, de 6 a 13 años de edad...

#TheAkariFoundation #SareptaTherapeutics

Click Subscribe #SareptaTherapeutics #SRPT #StockMarket #Investing #FinanceNews

Sarepta shares slide again as drugmaker bows to FDA pressure to pause gene therapy Sarepta Therapeutics is pausing shipments of its gene therapy for muscular dystrophy following several patient deaths that have attracted attention from regulators.

Shares of drugmaker #SareptaTherapeutics sink after the company said it would comply w a #FDA request to pause shipments of its #GeneTherapy several patient deaths.

The decision-comes days after the company rebuffed FDA regulators in an extremely unusual decision that #alarmed investors & analysts.

Two Weeks After Ouster Prompted By Laura Loomer, Vinay Prasad Back At FDA - IndiaWest Journal News Two Weeks After Ouster Prompted By Laura Loomer, Vinay Prasad Back At FDA.

Two Weeks After Ouster Prompted By Laura Loomer, Vinay Prasad Back At FDA

Full Story: indiawest.com/two-weeks-af...

#VinayPrasad #FDAReinstatement #LauraLoomer #FDALeadership #VaccineRegulation #GeneTherapy #SareptaTherapeutics #DuchenneMD #FDAControversy

Sarepta reanudará próximamente los envíos de ELEVIDYS a los centros de cuidado para el tratamiento de pacientes ambulatorios con Duchenne.

🔗Lee el artículo completo en el siguiente link: lnkd.in/erwmDCDW

#TheAkariFoundation #DistrofiaMuscularDeDuchenne #SareptaTherapeutics #ELEVIDYS

Sarepta Therapeutics stock tumbles on concern about FDA study requirements Investing.com -- Sarepta Therapeutics (NASDAQ:SRPT) stock fell 20% Thursday, extending recent declines after reports that the company would need to conduct new studies to return its Duchenne muscular dystrophy treatment to the market. According to Endpoints News, FDA officials stated that the Center for Biologics Evaluation and Research (CBER) review staff are "unanimous" that Elevidys should never return to market. The report indicates Sarepta would be required to conduct new studies before any potential market reintroduction. The decline follows Sarepta’s Monday announcement that it would voluntarily and temporarily pause all shipments of Elevidys in the United States. This decision came after the death of a 51-year-old non-ambulant Limb-Girdle Muscular Dystrophy patient. Elevidys (delandistrogene moxeparvovec) is Sarepta’s gene therapy treatment for Duchenne muscular dystrophy, a rare genetic disorder characterized by progressive muscle degeneration and weakness. The stock has faced significant pressure as investors assess the potential timeline and costs associated with conducting additional studies, as well as uncertainty around whether the treatment can eventually return to market. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Sure, there are always opportunities in the stock market – but finding them feels more difficult now than a year ago. Unsure where to invest next? One of the best ways to discover new high-potential opportunities is to look at the top performing portfolios this year. ProPicks AI offers 6 model portfolios from Investing.com which identify the best stocks for investors to buy right now. For example, ProPicks AI found 9 overlooked stocks that jumped over 25% this year alone. The new stocks that made the monthly cut could yield enormous returns in the coming years. Is SRPT one of them?

Click Subscribe #SareptaTherapeutics #StockMarket #FDA #Pharmaceuticals #InvestmentNews

🔗Lee el artículo completo en el siguiente link: theakarifoundation-pr.org/blog/

#TheAkariFoundation #sanantoniotexas #enfermedadesraras #DistrofiaMuscularDeCinturas #LGMD #SareptaTherapeutics #somoselcorazóndeladistrofia #AkariJulio

Sarepta Shares Sink After Third Patient Death Raises Safety Concerns Over Gene Therapies Sarepta Therapeutics (SRPT) is once again under scrutiny after confirming that a third patient has died following treatment with one of its gene therapy candida

#SRPT
#SareptaTherapeutics shares tumble following a third reported patient death linked to its gene therapy program, sparking renewed safety concerns. The company faces growing scrutiny as it defends the treatment's benefit-risk profile.
prismmarketview.com/sarepta-shar...

Sarepta Therapeutics Stock Tumbles on Report of Third Death in Clinical Trial - Investopedia Sarepta Therapeutics Stock Tumbles on Report of Third Death in Clinical Trial  Investopedia

Click Subscribe #SareptaTherapeutics #ClinicalTrials #StockMarket #Investopedia #PharmaceuticalNews

Sarepta Therapeutics anunció una reestructuración estratégica en la compañía y un plan de priorización de la línea de desarrollo para asegurar mantenerse como una compañía sostenible hacia el futuro, capaz de mantener su misión para la comunidad Duchenne.

#TheAkariFoundation #SareptaTherapeutics

Class Action Lawsuit Filed Against Sarepta Therapeutics Over Elevidys Treatment Concern Pomerantz Law Firm notifies investors about a class action lawsuit against Sarepta Therapeutics related to serious allegations of securities fraud. Deadline approaching.

Class Action Lawsuit Filed Against Sarepta Therapeutics Over Elevidys Treatment Concern #United_States #New_York #ClassAction #ELEVIDYS #SareptaTherapeutics

En una carta a la comunidad Duchenne, Sarepta Therapeutics anunció que suspenderá los envíos comerciales de Elevidys para pacientes con DMD que no pueden caminar.

🔗Lee el artículo completo en el link: lnkd.in/de_Ad9SR

#TheAkariFoundation #DistrofiaMuscularDeDuchenne #Elevidys #SareptaTherapeutics

Sarepta ha dicho que se sigue avanzando en los tratamientos SRP-9003 y SRP-9004, dos terapias génicas que ya se están evaluando clínicamente para otros tipos de LGMD🔬

🔗Lee el artículo completo en el link: lnkd.in/e5U2u9XS

#TheAkariFoundation #DistrofiaMuscularDeCinturas #LGMD #SareptaTherapeutics

Este evento fue un espacio de comunidad, aprendizaje y esperanza. Vernos, escucharnos y apoyarnos nos recuerda que no estamos solos en este camino.🤝💙

#SareptaTherapeutics #NSPharma #EdgewiseTherapeutics #PTCTherapeutics #CatalystPharmaceuticals #ITFTherapeutics #AvidityBiosciences

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost - Investor's Business Daily Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost  Investor's Business Daily

Click Subscribe #Genetics #SareptaTherapeutics #Biotech #Investing #StockMarket

NOTA: En The Akari Foundation lamentamos mucho está perdida, deseando fortaleza y consuelo a su familia y seres queridos.

También recordamos que este tipo de sucesos son pocos frecuentes y la ciencia sigue avanzando y trabajando en el tratamiento de la DMD

#TheAkariFoundation #SareptaTherapeutics